Tag: investors

Singapore , July 01, 2025 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce its acquisition of Pesticide Pest Control Pte. Ltd., a Singapore-based pest control company with over 30 years of operational history.

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1

Golar LNG's 2^nd Quarter 2025 results will be released before the NASDAQ opens on Thursday, August 14, 2025. In connection with this a webcast presentation will be held at 1:00 P.M (London Time) on Thursday August 14, 2025. The presentation will be available to download from the Investor Relations section at www.golarlng.com

Paris, July 1st, 2025 – Virtune AB, the Swedish regulated crypto asset manager, today announced the listing of Virtune Coinbase 50 Index ETP (VCOIN50) on Euronext Paris. The exchange-traded product (ETP) is now available to investors in France through brokers and banks.

Rincell-1 addresses a multi $Bn global market opportunity  where no disease modifying treatments currently exist

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.